CANCER IN CHILDREN

加州大学儿科血液科-肿瘤科 密歇根医学中心在所有儿童开放研究中进行合作 癌症小组，目标是改善儿童的护理和存活率 得了癌症。该分部是密歇根大学癌症分校的成员 NC.I.综合癌症中心，该州的两个癌症中心之一 ，拥有9名全职临床研究人员和教职员工 密歇根大学医学院的预约，以及 批准的儿科血液肿瘤学奖学金计划 每三年培训一次的研究员。此外，参与 CCG研究活动通过协作得到加强-有五个 位于密歇根州人口较多地区的附属机构 (底特律地区两个，大急流城一个，东兰辛一个，以及 卡拉马祖有一家)；附属机构的数量从一家增加到 在上次竞标时续签到目前的五家。CCG患者 截至本年度，来自附属公司网络的注册数量为176 1992年7月31日(在CCG院校中排名第14位)，总学习 同年条目数为237个(在CCG机构中排名第六)；99个 其中一线治疗研究条目(在CCG中排名第八 机构)，132项为非治疗性研究条目(在CCG中排名第三 机构)。此外，该网络积极跟踪795名患者 (在CCG机构中排名第十)。这些数字都要高得多 比起上次竞聘，随着人数的跟进更多 是1988年的两倍还多。密歇根大学是17所大学之一 CCG机构获准参加第一阶段的研究，是 CCG批准的骨髓移植中心，后者批准自 最后一份参赛作品。共有11个多学科 调查人员有科学、纪律和研究的约会 委员会和战略小组。在未来，这些调查人员在 密歇根大学将继续为CCG治疗做出贡献， 流行病学，以及对多种恶性疾病的生物学研究。 预计在I期临床领域将有更多的贡献。 小径和骨髓移植。最后，新的调查人员在 儿科血液学-大学肿瘤学目前正在进行 神经母细胞瘤和软组织的分子生物学贡献 肉瘤；这些研究可能会扩展到CCG的临床试验 为了评估临床相关性和预后的重要性 调查结果。

The Division of Pediatric Hematology-Oncology at the University of Michigan Medical Center collaborates in all open studies of the Childrens Cancer Group, with the goal of improving the care and survival of children with cancer. The Division is a member of the University of Michigan Cancer Center, an N.C.I. Comprehensive Cancer Center, one of two in the State of Michigan, and has nine full-time clinical investigators with faculty appointments at the University of Michigan Medical School, as well as an approved fellowship program in pediatric hematology-oncology with two fellows in training for each of three years. In addition, participation in CCG research activities is enhanced through collaboration - with five affiliate institutions located in the more populous regions of Michigan (two in the Detroit area, one in Grand Rapids, one in East Lansing, and one in Kalamazoo); the number of affiliate institutions has grown from one at the time of the last competitive renewal to five currently. CCG patient registrations from the affiliate network numbered 176 for the year ending July 31, 1992 (fourteenth among CCG institutions), with total study entries equaling 237 for the same year (sixth among CCG institutions); 99 of these were first-line therapeutic study entries (eighth among CCG institutions), and 132 were non-therapeutic study entries (third among CCG institutions). Furthermore, the network actively follows 795 patients (tenth among CCG institutions). These numbers are all considerably higher than at last competitive application, with the number in follow-up more than double the number in 1988. The University of Michigan is one of 17 CCG institutions approved for participation in phase I studies and is a CCG-approved bone marrow transplant center, the latter approval new since the last competitive submission. A total of 11 multidisciplinary investigators have appointments to scientific, discipline, and study committees and to strategy groups. In the future, these investigators at the University of Michigan will continue to contribute to CCG therapeutic, epidemiology, and biology research for a wide range of malignant diseases. Additional contributions can be expected in the areas of phase I clinical trails and bone marrow transplantation. Finally, new investigators in Pediatric Hematology-Oncology at the University are currently making contributions to the molecular biology of neuroblastoma and soft tissue sarcoma; these studies will likely be expanded to clinical trials in CCG in order to evaluate the clinical relevance and the prognostic importance of the findings.